Rocket Pharmaceuticals is trading 5.75% down at $3.44 as investors take profits following Moderna-driven enthusiasm.
- No fresh company-specific announcement was identified for August 20, 2026.
- Recent updates highlighted positive Danon-disease safety data and second-quarter progress.
- Rising Treasury yields, lower major indexes and broader market weakness are also pressuring the shares.